Evidence map›Paper›PMID 37563269›Full record

ArticleNature nanotechnology2023

Author Correction: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.

Alexandre Detappe, Hung V-T Nguyen, Yivan Jiang, Michael P Agius, Wencong Wang, Clelia Mathieu, Nang K Su, Samantha L Kristufek, David J Lundberg, Sachin Bhagchandani and 3 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alexandre Detappe *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hung V-T Nguyen *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yivan JiangDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Michael P AgiusDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wencong WangDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9578-209X
Clelia MathieuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nang K SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Samantha L KristufekDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
David J LundbergDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sachin BhagchandaniDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7361-3092
P Peter GhoroghchianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ppg@mit.edu.
Jeremiah A JohnsonDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.ORCID http://orcid.org/0000-0001-9157-6491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37563269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.